Baoyue Pan
State Key Laboratory Of Oncology In South China
Guangzhou, China
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study.
Journal: Frontiers in immunology
Published: February 24, 2025
The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors.
Journal: Journal of ovarian research
Published: November 06, 2024
Targeting the Cdc2-like kinase 2 for overcoming platinum resistance in ovarian cancer.
Journal: MedComm
Published: September 05, 2023
The MYBL2-CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages.
Journal: Cancer cell international
Published: April 19, 2023
A Nomogram for Preoperative Prediction of the Risk of Lymph Node Metastasis in Patients with Epithelial Ovarian Cancer.
Journal: Current oncology (Toronto, Ont.)
Published: February 02, 2023
Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers.
Journal: Frontiers in immunology
Published: December 01, 2022
Methyltransferase-like 3 promotes cervical cancer metastasis by enhancing cathepsin L mRNA stability in an N6-methyladenosine-dependent manner.
Journal: Cancer science
Published: May 31, 2022
Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB.
Journal: Pathology oncology research : POR
Published: January 01, 2022
Pretreatment C-Reactive Protein/Albumin Ratio is Associated With Poor Survival in Patients With 2018 FIGO Stage IB-IIA HPV-Positive Cervical Cancer.
Journal: Pathology oncology research : POR
Published: July 11, 2021
Showing 1-11 of 11
Last Updated: 09/26/2026